Boniva ad hyped efficacy: DDMAC

Share this article:
A print ad for Genentech's Boniva overstated the osteoporosis drug's efficacy, said the FDA's DDMAC in an untitled letter.
The agency took issue with the claim in the ad, which features Sally Field, that: “Studies show, after a year on Boniva, 9 out of 10 women stopped and reversed their bone loss.” The claim, said DDMAC, “is not supported by substantial evidence or substantial clinical experience” but rather “a per-protocol post-hoc responder analysis that the clinical study was not adequately designed to evaluate.” The ad that prompted the letter ran in Parade Magazine with the headline: “I wanted to stop my bone loss. But I did more. I reversed it with Boniva.”
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Pharmaceutical

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.